Prime Medicine Announces Closing of Public Offering
Prime Medicine completed an underwritten public offering of common stock, raising approximately $143.7 million in gross proceeds.
Stocks · News reference
Prime Medicine, Inc. has initiated an underwritten public offering of $125 million in common stock, with an additional option for underwriters to purchase more shares.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Prime Medicine completed an underwritten public offering of common stock, raising approximately $143.7 million in gross proceeds.
Prime Medicine, Inc. released its financial results for the third quarter ended September 30, 2026, and provided a business update.
Filed: 2026-11-12 AccNo: 0001628280-26-073131 Size: 501 KB Item 1.01: Entry into a Material Definitive Agreement
Prime Medicine, Inc. has priced an underwritten public offering of 35,714,286 shares of its common stock at $3.50 per share, expecting gross proceeds of approximately $125 million.
Prime Medicine, Inc. announced that its CEO, Allan Reine, M.D., will participate in a fireside chat at the upcoming Jefferies Global Healthcare Conference in London.
Prime Medicine, Inc. is set to release its financial results for the third quarter of 2026 on October 30, 2026.